About Us | Clearsky

ClearSky Medical Diagnostics specialises in developing digital technologies for the diagnosis and monitoring of Parkinson’s, Alzheimer’s, and other neurodegenerative conditions.

Originating from a collaboration with specialists from Leeds General Infirmary, Heriot-Watt University, and the University of York, the company was incorporated in 2013 by co-founder and director Dr. Stephen Smith, along with academic and industry investors.

In response to the stagnant diagnostic landscape of neurodegenerative conditions, ClearSky was founded on the vision of transforming healthcare through modern technologies and computer science. Our mission is to provide objective tools for assessing and monitoring these conditions, addressing challenges in accessibility and introducing clarity to medical diagnoses—reflecting our name, ClearSky, in understanding neuroscience. Over the past ten years, ClearSky has created a portfolio of non-invasive devices for safe, quick, and objective symptom assessment, making them ideal for clinical diagnostics and supporting research. Leveraging broad expertise in AI & Machine Learning, wearable technologies, clinical domains, and crucial commercialization aspects like regulatory affairs and pricing, ClearSky offers tailored, comprehensive AI/Machine Learning services for healthcare professionals and industry stakeholders seeking digital technology solutions.

Management Team

Prof Stephen Smith

Managing Director

Stephen is our Co-Founder and Director and a senior lecturer & academic researcher in the Department of Electronics at the University of York. Stephen’s research has focussed on the diagnosis, differentiation and monitoring of neurodegenerative conditions, such as Parkinson’s and Alzheimer’s. His determination to translate technology from theoretical studies through to widespread clinical adoption has led to collaborations with consultant neurologists and specialist nurses and the development of innovative and unique medical equipment for these conditions.

Harvey Dettmar

Finance Director

Harvey Dettmar has a background in technology and investment banking with a first class honour’s degree in Information Technology and an MBA with merit. Since 2003 Harvey has created and worked for a number of healthcare start-up companies in finance, operations and sales. Harvey also has valuable experience in selling to the NHS in the UK and developing and managing international distributors and partners.

Betty Su

Director

Betty Su is the Vice President at Veranex, a global CRO specializing in medical technologies, where she serves as the lead consultant for commercialization and market access strategy in the Asia Pacific region. With 25 years of industry and consulting experience, Ms. Su specializes in commercialization, regulatory affairs, and market access strategies for drug, device, and diagnostic technologies. She provides valuable insights to ClearSky on market access and commercialization opportunities.

Alex Lou

Commercialisation Director

Alex Lou leads ClearSky's commercial and business development endeavors, bringing over 20 years of entrepreneurial expertise to the table, with a specialization in fundraising, sales generation, and distributor management within the field of medical innovations. As a strategic leader, Alex has successfully navigated large-scale investment fundraising initiatives and played a pivotal role as an angel investor in numerous start-ups. Notably, he has a track record of securing funds from China for investment overseas, showcasing his proficiency in cross-border financial transactions.

AI and Machine Learning Team

Chief Scientific Officer

Dr Michael Lones

Michael is Associate Professor in the School of Mathematical and Computer Sciences, Heriot-Watt University, Edinburgh. His research covers topics in optimisation, data mining, medical informatics, systems biology and non-standard computation. His current work includes the diagnosis and understanding of neurodegenerative diseases, and the use of artificial biochemical networks for controlling robots and other complex systems.

Chief Technical Officer

Dr Amir Dehsarvi

TBA

Head of Product Development

Dr Cameron Harwood

TBA

Head of Machine Learning

Dr Marta Vallejo

TBA

Software Engineer -

AI and Machine Learning

Dr Victoria Hodge

TBA

Software Engineer -

AI and Machine Learning

Dr Iris Kyranou

TBA

Medical Advisers

DR STUART JAMIESON

Dr Jamieson has been a Consultant Neurologist at Leeds General Infirmary and Senior Lecturer in Neurology at the University of Leeds for more than twenty years. He is the senior member of the Yorkshire Movement Disorders Service and has extensive experience and knowledge of Parkinson’s disease, Huntington’s disease, dystonia and tremor managing thousands of patients with these disorders over the years.

DR JANE ALTY

Dr Alty is a Senior Lecturer in Neurology at Wicking Dementia Research & Education Centre at the University of Tasmania. Her previous role was Consultant Neurologist at Leeds Teaching Hospitals NHS Trust. She is a shareholder in ClearSky MD and was part of the team that won an international award from Hummies (prize money) for work on Parkinson’s dyskinesia.

DR SHENGDI CHEN

Professor Chen is the Chairman of the Department of Neurology at Ruijin Hospital, Shanghai Jiao Tong University School of Medicine. His interests focus on the epidemiology, pathogenesis, diagnosis and treatment of Parkinson's disease, Alzheimer's disease and related disorders. Professor Chen has published 450 original and review articles (including more than 90 SCI papers) and has rich experience in serving as editorial board members and reviewers for various journals across the field.

Get in Touch

ClearSky Medical Diagnostics
The Catalyst
Baird Lane
York

YO10 5GA

info@clearskymd.com
+44 (0)1904 322351

Our StoryOur Story

Management Team

AI and Machine Learning Team

Medical Advisers

Get in Touch